Researchers are pairing virtual reality therapy with low-dose psilocybin to help people practice stressful social situations such as interviews and group interactions in a controlled setting. The trial will test 3 mg doses taken every third day in 32 adults with social anxiety disorder, looking for improvements beyond therapy alone. If successful, it could open the door to new ways of treating one of the world's most common anxiety conditions.